There were no differences in terms of sex, age at diagnosis, clinical characteristics (except for arthritis), or MEFV mutations between treatment responders and those who did not respond to colchicine and were additionally given IL-1-targeting drugs (Tables 1 and Table 2). The gene discussed is MEFV; the disease is arthritic joint disease.